Its use however remains limited, particularly in the setting of ICI and cancer therapy, with possible associations of leptin therapy with immune effects on T cells, as well as unclear relationships with T cell lymphoma and activation of autoimmune renal or hepatic disease (22). The gene discussed is LEP; the disease is T-cell non-Hodgkin lymphoma.